Brittany C Davis
Biographic Data
| ID | 10433469 |
|---|---|
| NAME | Brittany C Davis |
| GIVEN NAMES | Brittany C |
| FAMILY NAME | Davis |
| SIGNATURE | DAVIS B C |
| VERIFIED | No |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Addressing pandemic-related guilt and shame in U.S. military veterans
Findings suggest that veterans with PTSD and guilt may benefit more from trauma- or morally injurious event-focused interventions like TrIGR, while veterans without PTSD may be adequately supported by SCT. Larger, more diverse samples are needed to identify optimal approaches for guilt and shame arising from morally injurious events. (PsycInfo Database Record (c) 2025 APA, all rights reserved)
Residual PTSD and depression symptoms among veterans receiving prolonged exposure therapy with and without topiramate
The residual symptoms most likely to persist may depend on the treatment being evaluated; topiramate may have unique effects on depressionogenic symptoms while patients are taking the medication. Residual symptoms may signal a need for additional treatment if they are distressing/functionally impairing. More work is needed to understand whether symptoms are maintained or continue to improve longitudinally. (PsycInfo Database Record (c) 2026 APA, …
A model for treating Covid-19–related guilt, shame, and moral injury
During the unprecedented COVID-19 pandemic, people around the world have faced a myriad of heart-rending and ethically difficult scenarios (e.g., not being able to tend to a sick or dying loved one) that may lead to subsequent guilt, shame, or moral injury. Trauma-informed guilt reduction therapy is a brief intervention that helps clients accurately appraise their role in a stressful event (such as those experienced during the COVID-19 pandemic) …
Does exposure exacerbate symptoms in veterans with PTSD and alcohol use disorder
Exposure therapy did not lead to more clinical exacerbation than nonexposure therapy during the course of treatment, providing support that exposure therapy should not be withheld from patients with PTSD/AUD. This was a secondary analysis. and future studies that are sufficiently powered may demonstrate different results. (PsycInfo Database Record (c) 2021 APA, all rights reserved)
No prominent works on this page.
A model for treating Covid-19–related guilt, shame, and moral injury
During the unprecedented COVID-19 pandemic, people around the world have faced a myriad of heart-rending and ethically difficult scenarios (e.g., not being able to tend to a sick or dying loved one) that may lead to subsequent guilt, shame, or moral injury. Trauma-informed guilt reduction therapy is a brief intervention that helps clients accurately appraise their role in a stressful event (such as those experienced during the COVID-19 pandemic) …
Does exposure exacerbate symptoms in veterans with PTSD and alcohol use disorder
Exposure therapy did not lead to more clinical exacerbation than nonexposure therapy during the course of treatment, providing support that exposure therapy should not be withheld from patients with PTSD/AUD. This was a secondary analysis. and future studies that are sufficiently powered may demonstrate different results. (PsycInfo Database Record (c) 2021 APA, all rights reserved)
Addressing pandemic-related guilt and shame in U.S. military veterans
Findings suggest that veterans with PTSD and guilt may benefit more from trauma- or morally injurious event-focused interventions like TrIGR, while veterans without PTSD may be adequately supported by SCT. Larger, more diverse samples are needed to identify optimal approaches for guilt and shame arising from morally injurious events. (PsycInfo Database Record (c) 2025 APA, all rights reserved)
Residual PTSD and depression symptoms among veterans receiving prolonged exposure therapy with and without topiramate
The residual symptoms most likely to persist may depend on the treatment being evaluated; topiramate may have unique effects on depressionogenic symptoms while patients are taking the medication. Residual symptoms may signal a need for additional treatment if they are distressing/functionally impairing. More work is needed to understand whether symptoms are maintained or continue to improve longitudinally. (PsycInfo Database Record (c) 2026 APA, …
Posttraumatic Stress Disorder Research (4 works) · PsycINFO (4 works) · Depression (economics (2 works) · Exposure therapy (2 works) · Medicine (2 works) · MEDLINE (2 works) · Moral injury (2 works) · Psychiatry (2 works) · Resilience and Mental Health (2 works) · Shame (2 works)